Low-dose statin therapy improves endothelial function in type 2 diabetic patients with normal serum total cholesterol: A randomized placebo-controlled study

Journal of Clinical Hypertension

Volumn 12, Issue 10, 2010, Pages 820-825

  Adel, Amr ^a   Abdel Salam, Zainab ^a   Nammas, Wail ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ADULT; ARTERY DIAMETER; ARTICLE; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; ENDOTHELIAL DYSFUNCTION; EXERCISE TEST; FEMALE; FOLLOW UP; HUMAN; HYPEREMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTICHOLESTEREMIC AGENTS; BRACHIAL ARTERY; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; EXERCISE TEST; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLACEBOS; PYRROLES; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 77957319698     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00367.x     Document Type: Article

References (19)

1. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22:36-52.
2. Pradhan AD, Cook NR, Buring JE. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 2003, 23:650-655.
3. Hennes MM, O'Shaughnessy IM, Kelly TM. Insulin resistant lipolysis in abdominally obese hypertensive individuals. Role of the renin-angiotensin system. Hypertension 1996, 28:120-126.
4. Anderson TJ, Meredith IT, Charbonneau F. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996, 93:1647-1650.
5. Laufs U, La Fata V, Plutzky J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
6. Boger RH. The emerging role of asymmetric dimethyl-arginine as a novel cardiovascular risk factor. Cardiovasc Res 2003, 59:824-833.
7. Tousoulis D, Antoniades C, Stefanadis C. Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques. Heart 2005, 91:553-558.
8. Lin KY, Ito A, Asagami T. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002, 106:987-992.
9. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995, 46:223-2234.
10. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991, 87:432-438.
11. Tsunekawa T, Hayashi T, Kano H. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001, 104:376-379.
12. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001, 49:281-287.
13. Ceriello A, Taboga C, Tonutti L. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002, 106:1211-1218.
14. van Venrooij FV, van de Ree MA, Bots ML. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2002, 25:1211-1216.
15. Economides PA, Caselli A, Tiani E. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004, 89:740-747.
16. Beishuizen ED, Tamsma JT, Jukema JW. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2005, 28:1668-1674.
17. Colhoun HM, Betteridge DJ, Durrington PN. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
18. Sever PS, Poulter NR, Dahlöf B. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005, 28:1151-1157.
19. Garg A. Statins for all patients with type 2 diabetes: not so soon. Lancet 2004, 364:641-642.